By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


UCB Group 

Allée de la Recherche, 60

Brussels    1070  Belgium
Phone: (32-2) 559-99-99 Fax: (32-2) 559-99-00


Company News
Dermira (DERM) And UCB Group (UCBJF.PK) Release: New CIMZIA (Certolizumab Pegol) Data In Moderate-To-Severe Plaque Psoriasis And Psoriatic Arthritis Presented At American Academy of Dermatology 2017 Annual Meeting 3/6/2017 10:58:52 AM
Dermira (DERM), UCB Group (UCBJF.PK) Release: Companies' Psoriasis Drug Wows In Phase III Study, Eyes Q3 Filing 1/19/2017 5:42:16 AM
MC10 And UCB Group (UCBJF.PK) Complete Landmark Pharmaceutical / Technology Collaboration Evaluating Patient Monitoring In Parkinson’s 1/5/2017 11:31:58 AM
Amgen (AMGN) And UCB Group (UCBJF.PK) Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab 9/27/2016 6:56:37 AM
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Showed Significant Results in Phase III Study 9/19/2016 5:52:37 AM
Syndax Expands Pipeline With Exclusive Worldwide License Agreement For UCB Group (UCBJF.PK)’s Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program 7/6/2016 8:05:34 AM
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Tops Teriparatide in Phase III Osteoporosis Study 4/4/2016 6:13:48 AM
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Shines in Phase III Osteoporosis Trial 3/21/2016 6:50:18 AM
U.S. FDA Approves UCB Group (UCBJF.PK)'s New Epilepsy Treatment, BRIVIACT, For Patients With Partial-Onset Seizures 2/22/2016 10:38:26 AM
Amgen (AMGN), UCB Group (UCBJF.PK)'s Osteoporosis Drug Comes Through in Late-Stage Study 2/22/2016 6:09:40 AM